• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球范围内前列腺特异性抗原检测政策差异很大,似乎不符合指南:系统评价。

Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review.

机构信息

Isala clinics, Department of Urology, Zwolle, The Netherlands.

出版信息

BMC Fam Pract. 2012 Oct 11;13:100. doi: 10.1186/1471-2296-13-100.

DOI:10.1186/1471-2296-13-100
PMID:23052017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3528621/
Abstract

BACKGROUND

Prostate specific antigen (PSA) testing is widely used, but guidelines on follow-up are unclear.

METHODS

We performed a systematic review of the literature to determine follow-up policy after PSA testing by general practitioners (GPs) and non-urologic hospitalists, the use of a cut-off value for this policy, the reasons for repeating a PSA test after an initial normal result, the existence of a general cut-off value below which a PSA result is considered normal, and the time frame for repeating a test. Data sources. MEDLINE, Embase, PsychInfo and the Cochrane library from January 1950 until May 2011. Study eligibility criteria. Studies describing follow-up policy by GPs or non-urologic hospitalists after a primary PSA test, excluding urologists and patients with prostate cancer. Studies written in Dutch, English, French, German, Italian or Spanish were included. Excluded were studies describing follow-up policy by urologists and follow-up of patients with prostate cancer. The quality of each study was structurally assessed.

RESULTS

Fifteen articles met the inclusion criteria. Three studies were of high quality. Follow-up differed greatly both after a normal and an abnormal PSA test result. Only one study described the reasons for not performing follow-up after an abnormal PSA result.

CONCLUSIONS

Based on the available literature, we cannot adequately assess physicians' follow-up policy after a primary PSA test. Follow-up after a normal or raised PSA test by GPs and non-urologic hospitalists seems to a large extent not in accordance with the guidelines.

摘要

背景

前列腺特异性抗原(PSA)检测被广泛应用,但针对该检测的后续随访方案并不明确。

方法

我们对文献进行了系统性回顾,以确定初级 PSA 检测后全科医生和非泌尿科医院医师的随访政策、用于制定该政策的 PSA 截断值、初次正常结果后重复 PSA 检测的原因、是否存在普遍的截断值使得 PSA 结果被认为正常,以及重复检测的时间框架。数据来源:1950 年 1 月至 2011 年 5 月间 MEDLINE、Embase、PsychInfo 和 Cochrane 图书馆。研究入选标准:描述初级 PSA 检测后全科医生或非泌尿科医院医师随访政策的研究,不包括泌尿科医生和前列腺癌患者。研究语言为荷兰语、英语、法语、德语、意大利语或西班牙语。排除描述泌尿科医生随访政策和前列腺癌患者随访的研究。对每篇研究的质量进行了结构性评估。

结果

符合纳入标准的研究共有 15 篇。其中 3 篇研究质量较高。正常和异常 PSA 检测结果后的随访差异很大。仅有一篇研究描述了异常 PSA 结果后未进行随访的原因。

结论

基于现有文献,我们无法充分评估医生在初次 PSA 检测后的随访政策。初级 PSA 检测后,全科医生和非泌尿科医院医师的正常或升高 PSA 检测随访在很大程度上不符合指南。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96de/3528621/11fa540060f8/1471-2296-13-100-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96de/3528621/11fa540060f8/1471-2296-13-100-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96de/3528621/11fa540060f8/1471-2296-13-100-1.jpg

相似文献

1
Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review.全球范围内前列腺特异性抗原检测政策差异很大,似乎不符合指南:系统评价。
BMC Fam Pract. 2012 Oct 11;13:100. doi: 10.1186/1471-2296-13-100.
2
Primary care professionals providing non-urgent care in hospital emergency departments.在医院急诊科提供非紧急护理的初级保健专业人员。
Cochrane Database Syst Rev. 2012 Nov 14;11:CD002097. doi: 10.1002/14651858.CD002097.pub3.
3
Interventions for promoting habitual exercise in people living with and beyond cancer.促进癌症患者及康复者进行习惯性锻炼的干预措施。
Cochrane Database Syst Rev. 2018 Sep 19;9(9):CD010192. doi: 10.1002/14651858.CD010192.pub3.
4
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
5
Lycopene for the prevention of prostate cancer.番茄红素用于预防前列腺癌。
Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD008007. doi: 10.1002/14651858.CD008007.pub2.
6
Primary care professionals providing non-urgent care in hospital emergency departments.在医院急诊科提供非紧急护理的基层医疗专业人员。
Cochrane Database Syst Rev. 2018 Feb 13;2(2):CD002097. doi: 10.1002/14651858.CD002097.pub4.
7
Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.使用经典和新型生物标志物作为局限性前列腺癌的预后危险因素:一项系统综述。
Health Technol Assess. 2009 Jan;13(5):iii, xi-xiii 1-219. doi: 10.3310/hta13050.
8
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
9
Interventions to improve antibiotic prescribing practices for hospital inpatients.改善医院住院患者抗生素处方行为的干预措施。
Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543. doi: 10.1002/14651858.CD003543.pub4.
10
MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis.磁共振成像软件联合认知融合活检用于疑似前列腺癌患者:系统评价、网络荟萃分析和成本效果分析。
Health Technol Assess. 2024 Oct;28(61):1-310. doi: 10.3310/PLFG4210.

引用本文的文献

1
Prostate Cancer Screening: Knowledge, Attitudes, and Practices by Medical Doctors in Portugal.葡萄牙医生对前列腺癌筛查的认知、态度和实践
J Cancer Educ. 2025 Jun 19. doi: 10.1007/s13187-025-02665-4.
2
Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey.德国泌尿科医生和全科医生对前列腺特异性抗原检测的态度及使用情况:一项调查
Front Oncol. 2021 Jun 4;11:691197. doi: 10.3389/fonc.2021.691197. eCollection 2021.
3
General practitioners' approaches to prostate-specific antigen testing in the north-east of the Netherlands.

本文引用的文献

1
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.前列腺癌筛查:美国预防服务工作组的证据回顾。
Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7.
2
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.前列腺癌筛查:随机对照试验的系统评价和荟萃分析。
BMJ. 2010 Sep 14;341:c4543. doi: 10.1136/bmj.c4543.
3
Pretest expectations strongly influence interpretation of abnormal laboratory results and further management.
荷兰东北部全科医生对前列腺特异性抗原检测的方法。
BMC Fam Pract. 2020 Dec 17;21(1):270. doi: 10.1186/s12875-020-01350-3.
4
Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists.使用前列腺特异性抗原检测早期发现前列腺癌:全科医生和泌尿科医生的实证评估。
Cancer Manag Res. 2019 Apr 16;11:3079-3097. doi: 10.2147/CMAR.S193325. eCollection 2019.
5
A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).在一项基于人群且有组织地进行前列腺特异性抗原筛查的研究中,家族史作为前列腺癌风险因素的研究:瑞士前列腺癌筛查欧洲随机研究(ERSPC,阿劳)的结果
BJU Int. 2016 Apr;117(4):576-83. doi: 10.1111/bju.13310. Epub 2015 Oct 6.
6
[Rates of prostate-specific antigen testing for early detection of prostate cancer: a first comparison of German results with current international data].[用于前列腺癌早期检测的前列腺特异性抗原检测率:德国结果与当前国际数据的首次比较]
Urologe A. 2014 May;53(5):715-24. doi: 10.1007/s00120-014-3453-0.
检验前的预期强烈影响对异常实验室结果的解读和进一步的管理。
BMC Fam Pract. 2010 Feb 16;11:13. doi: 10.1186/1471-2296-11-13.
4
Prostate specific antigen best practice statement: 2009 update.前列腺特异性抗原最佳实践声明:2009年更新版
J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24.
5
Screening and prostate-cancer mortality in a randomized European study.一项欧洲随机研究中的筛查与前列腺癌死亡率
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
6
Mortality results from a randomized prostate-cancer screening trial.一项前列腺癌随机筛查试验的死亡率结果。
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
7
Perception of abnormal serum prostate-specific antigen (PSA) test results amongst family practitioners.家庭医生对血清前列腺特异性抗原(PSA)检测异常结果的认知
Ann R Coll Surg Engl. 2008 Jul;90(5):398-402. doi: 10.1308/003588408X301019.
8
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.前列腺癌:欧洲医学肿瘤学会关于诊断、治疗及随访的临床建议
Ann Oncol. 2008 May;19 Suppl 2:ii45-6. doi: 10.1093/annonc/mdn084.
9
Urological referral of asymptomatic men in general practice in England.英国全科医疗中无症状男性的泌尿外科转诊
Br J Cancer. 2008 Apr 8;98(7):1176-81. doi: 10.1038/sj.bjc.6604291. Epub 2008 Mar 18.
10
[General practical survey of individual prostate cancer screening].[个体前列腺癌筛查的一般实践调查]
Prog Urol. 2008 Jan;18(1):46-52. doi: 10.1016/j.purol.2007.10.006. Epub 2008 Feb 25.